Ortho/Stratagene MAb technology
Two firms have rights to new E. coli-based monoclonal antibody technology developed at the Research Institute of the Scripps Clinic which potentially offers greater speed, variety and economy than the current mouse or human-based production media. Ortho parent J&J has the rights to license healthcare-related technologies developed by Scripps. The privately-held molecular biology products supplier Stratagene, has set up a new company, Stratacyte, to exploit and license the technology to the research community.
You may also be interested in...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.